<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228176</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5828</org_study_id>
    <secondary_id>2005-001612-49</secondary_id>
    <nct_id>NCT00228176</nct_id>
  </id_info>
  <brief_title>Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant</brief_title>
  <acronym>AUDITOR</acronym>
  <official_title>Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

        -  Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with
           placebo, on the quantitative progression of atherosclerosis as assessed by carotid
           artery intima-media thickness (CIMT)

        -  Secondary: To evaluate the safety and tolerability of the above rimonabant regimen in
           the study population of atherosclerosis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, prospective, multicentre, multinational, randomized, double-blind,
      placebo-controlled, 2-arm parallel group trial (rimonabant 20-mg od vs placebo). There will
      be a three-stage screening process including successively a Screening visit, a Screening CIMT
      and a validation of the Screening CIMT by the Imaging Core Laboratory. Patients complying
      with all inclusion and exclusion criteria will be randomized in one of the 2 treatment groups
      less than two weeks after Screening visit. Study drug (rimonabant 20 mg od or matching
      placebo) will be administered during 30 to 32 months. At inclusion, patients will be
      counseled to follow a mild hypocaloric diet, to increase their exercise level, and to stop
      smoking (if smokers). Glucose/lipid parameters will be assessed at Baseline and every 6
      months until the Month 30 visit. CIMT will be performed at Baseline and every 6 months until
      final assessment at Month 30 (primary endpoint).A post-treatment follow-up visit at Month 35
      will allow the collection of all adverse events and cardiovascular outcomes occurring after
      last study drug administration
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision taken in light of demands by certain national health authorities
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline in averaged per patient carotid artery intima-media thickness (CIMT)</measure>
    <time_frame>Month 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>First occurrence of any component of stroke/myocardial infarction (MI)/cardiovascular death</measure>
    <time_frame>From randomization to Month 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First occurrence of any component of stroke/MI/cardiovascular death/hospitalization for revascularization procedure, unstable angina, transient ischemic attack (TIA)</measure>
    <time_frame>From randomization to Month 35</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">661</enrollment>
  <condition>Carotid Artery Plaque</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Rimonabant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rimonabant 20 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Rimonabant) once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Rimonabant</arm_group_label>
    <other_name>SR141716</other_name>
    <other_name>Acomplia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Rimonabant)</intervention_name>
    <description>Tablet, oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written and signed informed consent

          -  Age greater than or equal to 55 years

          -  Abdominal obesity defined by waist circumference &gt; 88 cm (35 inches) in women and &gt;
             102 cm (40 inches) in men

          -  Metabolic syndrome diagnosed on the basis of at least two of the following additional
             risk factors:

               1. Triglyceride level equal to or greater than 150 mg/dL

               2. HDL cholesterol less than 40 mg/dL in men or 50 mg/dL in women

               3. Fasting glucose of equal to or greater than 110 mg/dL

               4. High blood pressure defined as equal to or greater than 140 mmHg systolic and/or
                  equal to or greater than 90 mmHg diastolic at screening visit or current
                  treatment by antihypertensive medication.

          -  Ultrasonographic evidence at Screening quantitative B-mode ultrasound imaging of a
             minimal CIMT measurement of greater than or equal to 0.7 mm in either of the far walls
             of the common carotid artery, and maximal CIMT measurement less than 3 mm in any
             carotid artery segment.

          -  All 6 carotid artery segments must have ultrasound images for all CIMT measurements

          -  Screening CIMT recording deemed to be of acceptable CIMT image quality, and
             demonstrating adherence to the CIMT interrogation protocol, as determined by the
             Imaging Core Laboratory's assessment.

        Exclusion Criteria:

          -  History of very low calorie diet or surgical procedures for weight loss within 6
             months prior to screening visit

          -  Obesity of known endocrine origin

          -  Uncontrolled diabetes, i.e. with HbA1c &gt; 10%

          -  Anticipated survival less than 27 months

          -  Presence of any severe medical or psychological condition, that in the opinion of the
             Investigator, would compromise the subject's safety or successful participation in the
             study

          -  Presence of any other condition (e.g. geographic, social, or other), actual or
             anticipated, that the Investigator feels would restrict or limit the subject's
             participation for the duration of the study

          -  Receipt of any investigational treatment (drug or device) within 30 days prior to
             Screening

          -  Previous participation in a rimonabant study

          -  Total occlusion of any carotid artery segment

          -  Previous history of carotid intervention

          -  Patient considered at high risk of carotid intervention during the next 27 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John JP Kastelein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Amsterdam Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>O'Leary DH, Reuwer AQ, Nissen SE, Despr√©s JP, Deanfield JE, Brown MW, Zhou R, Zabbatino SM, Job B, Kastelein JJ, Visseren FL; AUDITOR investigators. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart. 2011 Jul;97(14):1143-50. doi: 10.1136/hrt.2011.223446. Epub 2011 May 24.</citation>
    <PMID>21610270</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <disposition_first_submitted>April 21, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 21, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 20, 2016</disposition_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Carotid Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

